Clinical Trials Logo

Advanced Refractory Solid Tumors clinical trials

View clinical trials related to Advanced Refractory Solid Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04685473 Active, not recruiting - Clinical trials for Advanced Refractory Solid Tumors

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Start date: January 7, 2021
Phase: Phase 1
Study type: Interventional

T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines. In addition, oral administration of T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human cancers. In this study, safety, tolerability and pharmacokinetic (PK) of T-1101 (Tosylate) capsules will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2 will be determined.